Soligenix announces placement in BioMedWire editorial on rare diseases and breakthrough therapies.

Soligenix Inc. has been featured in an editorial published by BioMedWire, discussing the challenges of rare diseases among older Americans. The National Institutes of Health estimate that over 30 million people in the US have a rare disease, with most having no FDA-approved therapies. Age-related changes can mask or delay diagnosis, making older adults particularly vulnerable. Soligenix's placement in the editorial highlights the company's focus on rare disease treatments.